- Home
- IDYA
as 05-09-2025 4:00pm EST
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 1.5B | IPO Year: | 2019 |
| Target Price: | $53.58 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.45 - $44.42 | Next Earning Date: | 05-06-2025 |
| Revenue: | $7,000,000 | Revenue Growth: | -54.85% |
| Revenue Growth (this year): | 121.2% | Revenue Growth (next year): | 302.20% |
Latest IDEAYA Biosciences Inc. News
IDYA Breaking Stock News: Dive into IDYA Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
IDEAYA Gets FDA Clearance to Initiate Clinical Trial of Antibody Drug Conjugate Program in Solid Tumors
MT Newswires
4 days ago
IDEAYA Biosciences Posts Q1 Net Loss; Cash Runway Extended Through 2029
PR Newswire
4 days ago
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
PR Newswire
4 days ago
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
Insider Monkey
5 days ago
Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential
PR Newswire
12 days ago
IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events
PR Newswire
15 days ago
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
Ideaya Biosciences Completes Phase 3 Trial Design Meetings With FDA; Shares Up Pre-Bell
Compare IDYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IDYA IDEAYA Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.